Cardlytics, Inc. (NASDAQ:CDLX – Get Rating) Director John V. Balen purchased 1,000 shares of the company’s stock in a transaction dated Monday, May 9th. The shares were acquired at an average price of $28.35 per share, with a total value of $28,350.00. Following the transaction, the director now owns 33,097 shares in the company, valued at approximately $938,299.95. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
CDLX opened at $29.42 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.29 and a quick ratio of 1.10. The stock’s 50 day simple moving average is $47.56 and its 200 day simple moving average is $61.67. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -13.13 and a beta of 2.47. Cardlytics, Inc. has a 1 year low of $27.94 and a 1 year high of $134.91.
Cardlytics (NASDAQ:CDLX – Get Rating) last issued its earnings results on Monday, May 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.36. Cardlytics had a negative net margin of 25.06% and a negative return on equity of 13.81%. The firm had revenue of $67.93 million for the quarter, compared to analysts’ expectations of $65.84 million. During the same quarter last year, the business earned ($0.59) earnings per share. As a group, sell-side analysts anticipate that Cardlytics, Inc. will post -3.24 EPS for the current year.
A number of equities analysts have recently commented on CDLX shares. Needham & Company LLC decreased their price target on shares of Cardlytics from $85.00 to $60.00 and set a “buy” rating on the stock in a report on Tuesday, May 3rd. Zacks Investment Research upgraded Cardlytics from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a research report on Thursday, May 5th. Craig Hallum decreased their price objective on Cardlytics from $70.00 to $50.00 in a report on Tuesday, May 3rd. Finally, Wells Fargo & Company assumed coverage on shares of Cardlytics in a research note on Tuesday, April 5th. They issued an “overweight” rating and a $72.00 price objective for the company. Four investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $56.25.
Cardlytics Company Profile (Get Rating)
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Read More
- Get a free copy of the StockNews.com research report on Cardlytics (CDLX)
- Fifth Third Bancorp Stock Bestows Opportunity
- 3 Reasons Why Hostess Brands Could Be a Sweet Addition to Your Watchlist
- XPO Logistics Is A Logical Choice For InvestorsÂ
- 3 Online Education Stocks Investors Should Study
- If PetMeds Is A Good Buy There Will Be A Better SignalÂ
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.